When will Everolimus be launched in the country and the latest market trends

Everolimus (Everolimus), as a mTOR inhibitor, has been approved for marketing in China and is used for a variety of indications, including advanced renal cell carcinoma, neuroendocrine tumors, and immunosuppressive treatment after organ transplantation. It was launched earlier in China, providing patients with more treatment options, especially for patients who require long-term maintenance treatment. Its oral tablet form is easy to use and manage. The introduction of everolimus has enriched the domestic drug system for oncology and post-transplantation immune regulation and improved patient accessibility.

Currently, everolimus has been included in the domestic medical insurance system. Common specifications include 2.5mg30 tablets and 5mg30 tablets. The market price of the 2.5mg specification is about 2,000 yuan, while the price of the 5mg specification is in the range of three to four thousand yuan. Due to the existence of medical insurance reimbursement policies, the actual fees paid by patients may vary depending on the region and type of medical insurance. The price of everolimus is relatively stable and can meet the long-term clinical demand for medication. At the same time, medical insurance coverage also reduces the financial burden on patients.

In overseas markets, everolimus is also available in a variety of generic versions. The Laos version of Lucius is available in two specifications: 5mg 30 tablets and 10mg 30 tablets. The prices are around 8900 yuan and 1,700 yuan respectively, which is more economical than domestic original drugs. The Indian version is available in two specifications: 5mg10 tablets and 10mg10 tablets, with prices ranging between 700 and 800 yuan and 1200 to 1800 yuan, making it a feasible channel for overseas patients to obtain everolimus. Overseas generic drugs are low-priced and have basically the same ingredients as the original drugs, providing an alternative for patients with limited economic conditions.

Overall, everolimus has high clinical accessibility and price competitiveness in both domestic and foreign markets. Domestic medical insurance inclusion and market stability enable patients to receive safe and standardized long-term treatment. For overseas patients or users who want to obtain drugs through overseas channels, generic drugs have obvious price advantages, but they need to pay attention to formal purchasing channels and drug quality assurance. During clinical use, rational selection of drugs and specifications based on patient condition, economic conditions and accessibility can help optimize treatment effects and reduce economic burden.

Reference materials:https://www.drugs.com/